Soligenix (SNGX) Competitors $3.38 +0.02 (+0.45%) As of 01:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNGX vs. CLNN, MRSN, SCYX, RNXT, ALXO, OKUR, ESLA, CLSD, BTAI, and AKTXShould you be buying Soligenix stock or one of its competitors? The main competitors of Soligenix include Clene (CLNN), Mersana Therapeutics (MRSN), SCYNEXIS (SCYX), RenovoRx (RNXT), ALX Oncology (ALXO), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Clearside Biomedical (CLSD), BioXcel Therapeutics (BTAI), and Akari Therapeutics (AKTX). These companies are all part of the "pharmaceutical products" industry. Soligenix vs. Its Competitors Clene Mersana Therapeutics SCYNEXIS RenovoRx ALX Oncology OnKure Therapeutics Estrella Immunopharma Clearside Biomedical BioXcel Therapeutics Akari Therapeutics Clene (NASDAQ:CLNN) and Soligenix (NASDAQ:SNGX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Is CLNN or SNGX more profitable? Soligenix has a net margin of 0.00% compared to Clene's net margin of -10,386.36%. Clene's return on equity of 0.00% beat Soligenix's return on equity.Company Net Margins Return on Equity Return on Assets Clene-10,386.36% N/A -125.49% Soligenix N/A -274.76%-129.20% Do institutionals & insiders have more ownership in CLNN or SNGX? 23.3% of Clene shares are owned by institutional investors. Comparatively, 3.6% of Soligenix shares are owned by institutional investors. 35.3% of Clene shares are owned by insiders. Comparatively, 3.1% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts rate CLNN or SNGX? Clene presently has a consensus target price of $33.00, suggesting a potential upside of 519.14%. Soligenix has a consensus target price of $6.00, suggesting a potential upside of 75.70%. Given Clene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Clene is more favorable than Soligenix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17Soligenix 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media favor CLNN or SNGX? In the previous week, Clene had 2 more articles in the media than Soligenix. MarketBeat recorded 12 mentions for Clene and 10 mentions for Soligenix. Soligenix's average media sentiment score of 0.10 beat Clene's score of -0.35 indicating that Soligenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Clene 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Soligenix 1 Very Positive mention(s) 5 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings & valuation, CLNN or SNGX? Soligenix has lower revenue, but higher earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Soligenix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClene$340K156.61-$39.40M-$3.76-1.42Soligenix$120K122.09-$8.27M-$3.80-0.90 Which has more volatility and risk, CLNN or SNGX? Clene has a beta of 0.55, indicating that its share price is 45% less volatile than the S&P 500. Comparatively, Soligenix has a beta of 1.95, indicating that its share price is 95% more volatile than the S&P 500. SummaryClene beats Soligenix on 12 of the 17 factors compared between the two stocks. Get Soligenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNGX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNGX vs. The Competition Export to ExcelMetricSoligenixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$14.66M$3.11B$5.82B$9.73BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-0.9021.1130.9626.08Price / Sales122.09394.05464.73119.69Price / CashN/A43.0937.1558.38Price / Book7.948.109.136.38Net Income-$8.27M-$54.72M$3.26B$265.48M7 Day Performance22.84%2.29%2.08%1.81%1 Month Performance142.20%7.21%5.01%1.12%1 Year Performance-19.46%12.64%31.22%21.02% Soligenix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNGXSoligenix2.1337 of 5 stars$3.38+0.4%$6.00+77.8%-24.7%$14.48M$120K-0.8920Gap DownCLNNClene3.2071 of 5 stars$4.24+17.1%$33.00+678.3%+3.5%$36.17M$340K-1.13100Analyst ForecastHigh Trading VolumeMRSNMersana Therapeutics4.1992 of 5 stars$7.38+3.1%$56.60+666.9%-76.7%$35.73M$34.77M-0.50150SCYXSCYNEXIS1.0624 of 5 stars$0.80-4.5%N/A-54.3%$35.21M$3.75M-2.0160News CoverageAnalyst RevisionRNXTRenovoRx2.9115 of 5 stars$0.94-1.6%$7.25+671.3%-15.7%$34.94M$40K-2.476News CoverageShort Interest ↓Analyst RevisionALXOALX Oncology2.5501 of 5 stars$0.97+50.7%$3.30+239.9%-58.8%$34.50MN/A-0.4440Analyst RevisionGap DownHigh Trading VolumeOKUROnKure Therapeutics3.1862 of 5 stars$2.80+10.7%$32.33+1,054.8%N/A$34.18MN/A-0.58N/AESLAEstrella Immunopharma2.8359 of 5 stars$0.92+1.0%$16.00+1,640.1%-37.6%$33.73MN/A-3.54N/ACLSDClearside Biomedical2.2284 of 5 stars$0.43+0.7%$4.20+886.1%-60.1%$33.21M$4.17M-1.1530Negative NewsBTAIBioXcel Therapeutics4.5765 of 5 stars$5.67+3.5%$39.75+601.1%-52.0%$33.19M$2.27M-0.4590Short Interest ↓AKTXAkari Therapeutics2.3884 of 5 stars$1.00-1.0%$5.00+400.0%-74.2%$32.50MN/A0.009 Related Companies and Tools Related Companies Clene Competitors Mersana Therapeutics Competitors SCYNEXIS Competitors RenovoRx Competitors ALX Oncology Competitors OnKure Therapeutics Competitors Estrella Immunopharma Competitors Clearside Biomedical Competitors BioXcel Therapeutics Competitors Akari Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SNGX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWashington Thinks They Own Your Bank AccountWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredSilver’s Still Under $35… For Now.Silver is trading around $33—but insiders are betting on a $70 breakout by year’s end. With supply shrinkin...GoldenCrest Metals | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredOne tiny company just cracked Google’s $19B problemAn MIT lab recently cracked a code scientists had been chasing for decades… Turning a “miracle metal” from ...True Market Insiders | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Soligenix Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Soligenix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.